Aclaris Therapeutics Reports Q4/FY2025 Results, Extends Cash Runway to H2 2028, Advances Multiple Pipeline Programs
ACRS has more than doubled off its 52-week low of $1.05.
Summary
Aclaris Therapeutics announced Q4 and full year 2025 financial results, highlighting a reduced net loss and a strong cash position extending its runway into the second half of 2028, alongside significant advancements in its clinical pipeline.
Key Events · Earnings and Guidance · ACRS
-
Strong Cash Position and Extended Runway
Aclaris Therapeutics reported cash, cash equivalents, and marketable securities of $151.4 million as of December 31, 2025, sufficient to fund operations into the second half of 2028.
-
Reduced Net Loss in 2025
The company's net loss for Q4 2025 was $19.8 million, a significant reduction from $96.6 million in Q4 2024. Full year 2025 net loss was $64.9 million, down from $132.1 million in 2024.
-
ATI-052 Program Advancing Rapidly
Positive interim Phase 1a results for ATI-052 support rapid clinical advancement, with two Phase 1b proof-of-concept trials in Atopic Dermatitis and Asthma now underway, and top-line results expected in H2 2026.
-
Key Pipeline Milestones Expected in 2026
Top-line results from the Phase 2 trial of bosakitug in Atopic Dermatitis are anticipated in H2 2026, and an Investigational New Drug (IND) application for ATI-9494 is expected in H2 2026.
Analysis · ACRS · Life Sciences
Aclaris Therapeutics has reported its fourth quarter and full year 2025 financial results, demonstrating a significant reduction in net loss year-over-year. Critically, the company announced a strong cash position of $151.4 million, providing a runway to fund operations into the second half of 2028. This extended financial stability is a major de-risking event for a clinical-stage biopharmaceutical company. Furthermore, the filing details substantial progress across its pipeline, including positive interim Phase 1a results for ATI-052, the initiation of two Phase 1b proof-of-concept trials for ATI-052, and upcoming milestones for bosakitug and ATI-9494. The positive preclinical data for ATI-2138 in alopecia also adds to the long-term potential. Investors should monitor the upcoming data readouts and IND filing for continued pipeline momentum.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACRS was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $358.6M. The 52-week trading range was $1.05 to $4.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.